ICAM1 and diabetic kidney disease: Between 2016 and 2017, diabetic nephropathy was the primary focus of these studies with angiopoietin-like protein, apolipoprotein, intercellular adhesion molecule-1, and glycation end products being the primary effectors under evaluation.